187 related articles for article (PubMed ID: 35357901)
41. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
[TBL] [Abstract][Full Text] [Related]
42. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
[TBL] [Abstract][Full Text] [Related]
43. Tumor necrosis at FDG-PET is an independent predictor of outcome in diffuse large B-cell lymphoma.
Adams HJA; de Klerk JMH; Fijnheer R; Heggelman BGF; Dubois SV; Nievelstein RAJ; Kwee TC
Eur J Radiol; 2016 Jan; 85(1):304-309. PubMed ID: 26515992
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Values of Baseline
Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
[TBL] [Abstract][Full Text] [Related]
45. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535
[TBL] [Abstract][Full Text] [Related]
46. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
47. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
[TBL] [Abstract][Full Text] [Related]
48. Risk Assessment in Diffuse Large B-Cell Lymphoma by Combining Baseline Metabolic Tumor Volume and Peking Criteria When Evaluating Series
Yuan T; Zhang Y; Chen X; Wei M; Zhu H; Song Y; Yang Z; Zhu J; Wang X
Front Oncol; 2022; 12():876581. PubMed ID: 35530320
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma.
Alderuccio JP; Kuker RA; Barreto-Coelho P; Martinez BM; Miao F; Kwon D; Beitinjaneh A; Wang TP; Reis IM; Lossos IS; Moskowitz CH
Leuk Lymphoma; 2022 Jan; 63(1):43-53. PubMed ID: 34414842
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma.
Oiwa K; Fujita K; Lee S; Morishita T; Tsujikawa T; Negoro E; Hara T; Tsurumi H; Ueda T; Yamauchi T
Ann Hematol; 2023 May; 102(5):1141-1148. PubMed ID: 36951966
[TBL] [Abstract][Full Text] [Related]
51. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
Gupta N; Singh N
Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
[TBL] [Abstract][Full Text] [Related]
52. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of total metabolic tumor volume on
Chang CC; Cho SF; Chuang YW; Lin CY; Chang SM; Hsu WL; Huang YF
Oncotarget; 2017 Nov; 8(59):99587-99600. PubMed ID: 29245926
[TBL] [Abstract][Full Text] [Related]
54. Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
Chow A; Phillips M; Siew T; Cull G; Augustson B; Ward M; Joske D
Intern Med J; 2013 Aug; 43(8):932-9. PubMed ID: 23692386
[TBL] [Abstract][Full Text] [Related]
55. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
Wang F; Cui S; Lu L; Shao X; Yan F; Liu Y; He B; Wang J; Cao Y; Yue Y; Wang Y; Gu W
BMC Cancer; 2023 Nov; 23(1):1165. PubMed ID: 38030989
[TBL] [Abstract][Full Text] [Related]
56. Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen?
Jiang C; Ding C; Xu J; Teng Y; Chen J; Wang Z; Zhou Z
Clin Nucl Med; 2021 Jan; 46(1):1-7. PubMed ID: 33181743
[TBL] [Abstract][Full Text] [Related]
57.
Burggraaff CN; Eertink JJ; Lugtenburg PJ; Hoekstra OS; Arens AIJ; de Keizer B; Heymans MW; van der Holt B; Wiegers SE; Pieplenbosch S; Boellaard R; de Vet HCW; Zijlstra JM;
J Nucl Med; 2022 Jul; 63(7):1001-1007. PubMed ID: 34675112
[TBL] [Abstract][Full Text] [Related]
58. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
59. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.
Ceriani L; Gritti G; Cascione L; Pirosa MC; Polino A; Ruberto T; Stathis A; Bruno A; Moccia AA; Giovanella L; Hayoz S; Schär S; Dirnhofer S; Rambaldi A; Martinelli G; Mamot C; Zucca E
Blood Adv; 2020 Mar; 4(6):1082-1092. PubMed ID: 32196557
[TBL] [Abstract][Full Text] [Related]
60. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
